Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSTL Stock Forecast 2026-2027
$21.01
Current Price
$637.23M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSTL Price Targets
+147.5%
To High Target of $52.00
+109.4%
To Median Target of $44.00
+66.6%
To Low Target of $35.00
CSTL Price Momentum
-0.3%
1 Week Change
-15.1%
1 Month Change
+19.4%
1 Year Change
-46.0%
Year-to-Date Change
-52.6%
From 52W High of $44.28
+44.0%
From 52W Low of $14.59
📊 TOP ANALYST CALLS
Did CSTL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Castle Biosciences is one of their latest high-conviction picks.
Latest CSTL Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CSTL has a bullish consensus with a median price target of $44.00 (ranging from $35.00 to $52.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $21.01, the median forecast implies a 109.4% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSTL Analyst Ratings
8
Buy
0
Hold
0
Sell
CSTL Price Target Range
Low
$35.00
Average
$44.00
High
$52.00
Current: $21.01
Latest CSTL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSTL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | BTIG | Mark Massaro | Buy | Maintains | $40.00 |
| May 7, 2026 | Baird | Catherine Ramsey | Outperform | Maintains | $43.00 |
| Apr 20, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 27, 2026 | Baird | Outperform | Maintains | $N/A | |
| Jan 26, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Jan 12, 2026 | Lake Street | Buy | Maintains | $N/A | |
| Jan 5, 2026 | Guggenheim | Buy | Maintains | $N/A | |
| Dec 22, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 12, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 5, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 4, 2025 | Baird | Outperform | Maintains | $N/A | |
| Sep 9, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| May 21, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| May 6, 2025 | Lake Street | Buy | Maintains | $N/A | |
| May 6, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Feb 28, 2025 | Baird | Outperform | Maintains | $N/A | |
| Jan 2, 2025 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Nov 6, 2024 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Nov 5, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Nov 5, 2024 | Keybanc | Overweight | Maintains | $N/A |
Castle Biosciences, Inc. (CSTL) Competitors
The following stocks are similar to Castle Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CSTL
Castle Biosciences
mkt cap
639.36M
Castle Biosciences, Inc. (CSTL) Financial Data
Castle Biosciences, Inc. has a market capitalization of $637.23M with a P/E ratio of 30.5x. The company generates $339.92M in trailing twelve-month revenue with a -3.8% profit margin.
Revenue growth is -4.9% quarter-over-quarter, while maintaining an operating margin of -22.0% and return on equity of -2.8%.
Valuation Metrics
Market Cap
$637.23M
Enterprise Value
$412.27M
P/E Ratio
30.5x
PEG Ratio
-0.7x
Price/Sales
1.9x
Growth & Margins
Revenue Growth (YoY)
-4.9%
Gross Margin
+75.5%
Operating Margin
-22.0%
Net Margin
-3.8%
EPS Growth
-4.9%
Financial Health
Cash/Price Ratio
+41.1%
Current Ratio
6.7x
Debt/Equity
8.0x
ROE
-2.8%
ROA
-4.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Castle Biosciences, Inc. (CSTL) Business Model
About Castle Biosciences, Inc.
What They Do
Develops gene expression profile tests for oncology.
Business Model
Castle Biosciences generates revenue by providing molecular diagnostic tests that help guide treatment decisions in oncology. Their tests, including DecisionDx and TissueCypher, are designed to stratify patient risk and inform personalized treatment pathways, enhancing clinical decision-making for physicians dealing with various types of cancer.
Additional Information
Founded in 2008 and based in Friendswood, Texas, the company emphasizes precision medicine and aims to improve patient outcomes through accurate diagnostics. Its innovative testing solutions are particularly valuable in managing dermatologic cancers and conditions affecting the esophagus.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
942
CEO
Mr. Derek J. Maetzold
Country
United States
IPO Year
N/A
Website
castlebiosciences.comCastle Biosciences, Inc. (CSTL) Latest News & Analysis
Latest News
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
25 days ago
Quick Summary
Castle Biosciences (Nasdaq: CSTL) won the "Genomics Innovation Award" for its AdvanceAD-Tx test at the MedTech Breakthrough Awards, marking its fifth such accolade for innovative health solutions.
Why It Matters
Castle Biosciences' fifth MedTech Breakthrough Award highlights its innovation and credibility in the healthcare sector, potentially boosting investor confidence and driving stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) will present a company overview at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 1:20 p.m. ET.
Why It Matters
Castle Biosciences' presentation at a major healthcare conference could signal growth and innovation, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences, Inc. (CSTL) held its Q1 2026 earnings call, discussing financial performance and key developments for the quarter. Further details are available in the full transcript.
Why It Matters
The Q1 2026 earnings call for Castle Biosciences provides insights into financial performance and growth prospects, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences reported Q1 2026 revenue of $83.7 million, a 36% increase in test reports. It raised full-year revenue guidance to $345-355 million. Conference call today at 4:30 p.m. ET.
Why It Matters
Castle Biosciences reported strong Q1 2026 revenue and a 36% increase in test reports, prompting an upward revision of annual revenue guidance, indicating robust growth potential and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences, Inc. (CSTL) reported a quarterly loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.56 loss, compared to a $0.2 loss per share a year earlier.
Why It Matters
Castle Biosciences' smaller-than-expected quarterly loss indicates improving financial performance, which may boost investor confidence and affect stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Castle Biosciences, Inc. announced that Mayo Clinic research shows the TissueCypher test enhances risk stratification and influences patient management decisions, with findings to be presented at DDW 2026.
Why It Matters
The TissueCypher test's improved risk stratification can enhance patient management, potentially increasing demand for Castle Biosciences' products and boosting its market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CSTL Stock
What is Castle Biosciences, Inc.'s (CSTL) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Castle Biosciences, Inc. (CSTL) has a median price target of $44.00. The highest price target is $52.00 and the lowest is $35.00.
Is CSTL stock a good investment in 2026?
According to current analyst ratings, CSTL has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $21.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSTL stock?
Wall Street analysts predict CSTL stock could reach $44.00 in the next 12 months. This represents a 109.4% increase from the current price of $21.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Castle Biosciences, Inc.'s business model?
Castle Biosciences generates revenue by providing molecular diagnostic tests that help guide treatment decisions in oncology. Their tests, including DecisionDx and TissueCypher, are designed to stratify patient risk and inform personalized treatment pathways, enhancing clinical decision-making for physicians dealing with various types of cancer.
What is the highest forecasted price for CSTL Castle Biosciences, Inc.?
The highest price target for CSTL is $52.00 from at , which represents a 147.5% increase from the current price of $21.01.
What is the lowest forecasted price for CSTL Castle Biosciences, Inc.?
The lowest price target for CSTL is $35.00 from at , which represents a 66.6% increase from the current price of $21.01.
What is the overall CSTL consensus from analysts for Castle Biosciences, Inc.?
The overall analyst consensus for CSTL is bullish. Out of 3 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $44.00.
How accurate are CSTL stock price projections?
Stock price projections, including those for Castle Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 5:36 PM UTC